Abstract:ABSTRACT The World Health Organization’s goal to combat tuberculosis (TB) is hindered by the emergence of anti-microbial resistance, therefore necessitating the exploration of new drug targets. Multidrug regimens are indispensable in TB therapy as they provide synergetic bactericidal effects, shorten treatment duration, and reduce the risk of resistance development. The research within our European RespiriTB consortium explores Mycobacterium tuberculosis energy metabolism to identify new drug candidates that synergize with bedaquiline, with the aim of discovering more efficient combination drug regimens. In this study, we describe the development and validation of a luminescence-coupled, target-based assay for the identification of novel compounds inhibiting Mycobacterium tuberculosis mycothione reductase (Mtr Mtb ), an enzyme with a role in the protection against oxidative stress. Recombinant Mtr Mtb was employed for the development of a highly sensitive, robust high-throughput screening (HTS) assay by coupling enzyme activity to a bioluminescent readout. Its application in a semi-automated setting resulted in the screening of a diverse library of ~130,000 compounds, from which 19 hits were retained after an assessment of their potency, selectivity, and specificity. The selected hits formed two clusters and four fragment molecules, which were further evaluated in whole-cell and intracellular infection assays. The established HTS discovery pipeline offers an opportunity to deliver novel Mtr Mtb inhibitors and lays the foundation for future efforts in developing robust biochemical assays for the identification and triaging of inhibitors from high-throughput library screens. IMPORTANCE The growing anti-microbial resistance poses a global public health threat, impeding progress toward eradicating tuberculosis. Despite decades of active research, there is still a dire need for the discovery of drugs with novel modes of action and exploration of combination drug regimens. Within the European RespiriTB consortium, we explore Mycobacterium tuberculosis energy metabolism to identify new drug candidates that synergize with bedaquiline, with the aim of discovering more efficient combination drug regimens. In this study, we present the development of a high-throughput screening pipeline that led to the identification of M. tuberculosis mycothione reductase inhibitors.

Rapid Gene Silencing Followed by Antimicrobial Susceptibility Testing for Target Validation in Antibiotic Discovery

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

A soft-computation hybrid method for search of the antibiotic-resistant gene in Mycobacterium tuberculosis for promising drug target identification and antimycobacterial lead discovery

Application of CRISPR–cas-based technology for the identification of tuberculosis, drug discovery and vaccine development

Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system

Weak links: Advancing target‐based drug discovery by identifying the most vulnerable targets

Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis

Reprogramming Mycobacterium Tuberculosis CRISPR System for Gene Editing and Genome-wide RNA Interference Screening

Modified HT-SPOTi: An Antimicrobial Susceptibility Testing to Evaluate Formulated Therapeutic Combinations Against Bacterial Growth and Viability

Antibiotic lethality dictates mycobacterial infection outcomes

Using Microfluidic Chip and Allele-Specific PCR to Rapidly Identify Drug Resistance-Associated Mutations of Mycobacterium tuberculosis

Engineered Mycobacteriophage TM4:: GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates

High-throughput nanopore targeted sequencing for efficient drug resistance assay of Mycobacterium tuberculosis

Application of Combined CRISPR Screening for Genetic and Chemical-Genetic Interaction Profiling in Mycobacterium Tuberculosis

Mycobacterium Tuberculosis Functional Genetic Diversity, Altered Drug Sensitivity, and Precision Medicine.

Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

Identification of gene targets that potentiate the action of rifampicin on Mycobacterium bovis BCG

A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors

ACURAT: Advancing Tuberculosis Detection Through Assembled PCR & CRISPR for Ultra-Sensitive Rifampin-resistant Analysis Testing

Genetics-directed Drug Discovery for Combating Mycobacterium Tuberculosis Infection